JOURNAL ARTICLE
REVIEW

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

Paolo Spagnolo, Oliver Distler, Christopher J Ryerson, Argyris Tzouvelekis, Joyce S Lee, Francesco Bonella, Demosthenes Bouros, Anna-Maria Hoffmann-Vold, Bruno Crestani, Eric L Matteson
Annals of the Rheumatic Diseases 2020 October 9
33037004
Interstitial lung diseases (ILDs), which can arise from a broad spectrum of distinct aetiologies, can manifest as a pulmonary complication of an underlying autoimmune and connective tissue disease (CTD-ILD), such as rheumatoid arthritis-ILD and systemic sclerosis (SSc-ILD). Patients with clinically distinct ILDs, whether CTD-related or not, can exhibit a pattern of common clinical disease behaviour (declining lung function, worsening respiratory symptoms and higher mortality), attributable to progressive fibrosis in the lungs. In recent years, the tyrosine kinase inhibitor nintedanib has demonstrated efficacy and safety in idiopathic pulmonary fibrosis (IPF), SSc-ILD and a broad range of other fibrosing ILDs with a progressive phenotype, including those associated with CTDs. Data from phase II studies also suggest that pirfenidone, which has a different-yet largely unknown-mechanism of action, may also have activity in other fibrosing ILDs with a progressive phenotype, in addition to its known efficacy in IPF. Collectively, these studies add weight to the hypothesis that, irrespective of the original clinical diagnosis of ILD, a progressive fibrosing phenotype may arise from common, underlying pathophysiological mechanisms of fibrosis involving pathways associated with the targets of nintedanib and, potentially, pirfenidone. However, despite the early proof of concept provided by these clinical studies, very little is known about the mechanistic commonalities and differences between ILDs with a progressive phenotype. In this review, we explore the biological and genetic mechanisms that drive fibrosis, and identify the missing evidence needed to provide the rationale for further studies that use the progressive phenotype as a target population.

Full Text Links

We have located open access full text paper links.

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Responses

Sort by: Most RecentHighest Rated

Dalia Amr

Check INBUILD subgroup analysis for CTD ILDS

RELIEF study pirfenadone

0

Dalia Amr

Nintedanib is a small molecule tyrosine kinase inhibitor that targets receptor tyrosine kinases involved in fibrosis, including those for PDGF, fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF) and TGF-β, as well as non-receptor kinases involved in inflammation and proliferation (Src family kinases), and activation and polarisation of macrophages (colony-stimulating factor-1).37 38 Nintedanib also inhibits the proliferation of vascular cells39 and modulates fibroblast activity

-1

Trending Papers

Remove bar
Read by QxMD icon Read
33037004
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"